Visual Function Changes After Intraocular Pressure Reduction
During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.
Drug: timolol maleate 0,5%
Drug: brimonidine tartrate 0,2%
Drug: travoprost 0,004%
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial|
- intraocular pressure
- contrast sensitivity
- visual quality perception
- Mean deviation of the visual field (MD)
- Pattern Standard Deviation of the visual field (PSD)
- visual acuity
|Study Start Date:||September 2005|
|Estimated Study Completion Date:||April 2006|
Primary open angle glaucoma patients without use of antiglaucoma medications will be enrolled in this study. After inclusion, the patients will randomly receive one of three antiglaucoma medications (timolol maleate 0,5%, brimonidine tartrate 0,2% or travoprost 0,004%) in one randomly selected eye.
The patients will be evaluated with Goldmann applanation tonometry, visual acuity test, contrast sensitivity test, visual quality perception test (visual analogue scale) and standard automated perimetry before and after 4 weeks of glaucoma treatment onset.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00435058
|Principal Investigator:||Tiago Prata, MD||Federal University of Sao Paulo|
|Principal Investigator:||Luiz A Melo Jr, MD||Federal University of Sao Paulo|